Is Semaglutide Still in Shortage in 2026?
Last updated: January 2026
Quick Answer
Novo Nordisk declared the shortage resolved in early 2025, which triggered FDA restrictions on compounding. However, compounded semaglutide remains available through many telehealth platforms while legal challenges continue. Check with your provider for current status.
Is Semaglutide Still in Shortage in 2026
Novo Nordisk declared the shortage resolved in early 2025, which triggered FDA restrictions on compounding. However, compounded semaglutide remains available through many telehealth platforms while legal challenges continue. Check with your provider for current status.
Choosing the right GLP-1 telehealth provider affects your treatment experience, costs, and outcomes. Key factors to compare include pricing transparency, medication options, provider credentials, support level, and insurance acceptance.
What to Look for in a Provider
- Licensed healthcare providers (physicians, NPs, or PAs) doing the prescribing
- Medications sourced from FDA-regulated or 503B compounding pharmacies
- Transparent pricing with no hidden enrollment or shipping fees
- Regular follow-up appointments included in the monthly cost
- Responsive customer support and easy prescription management
Our Top Recommendation
Remedy Meds is our top-rated provider with a 4.7/5 rating, offering $199-399/mo pricing with board-certified providers and free assessment. They serve patients across all 50 states with home medication delivery.
Learn more about this medication: Semaglutide Complete Guide
Related Questions
What Does the FDA Say About Compounded Semaglutide?
The FDA allowed compounding during the semaglutide shortage (2023-2024). In 2025, after declaring the shortage resolved, the FDA moved to restrict compounding. Legal challenges from compounding pharmacies have kept access open in many states. Status continues to evolve.
What is the Difference Between Compounded and Brand Semaglutide?
Same active molecule (semaglutide). Brand-name (Wegovy/Ozempic) comes from the original manufacturer in a standardized pen. Compounded versions are made by 503A/503B pharmacies, often in vials, at 80-85% lower cost. Clinical outcomes appear comparable when properly dosed.